http://new.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Wed, 09 Sep 2026 06:12:24 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://new.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/New+Coverage/H.C.+Wainwright+Starts+TriSalus+Life+Sciences%2C+Inc.+%28TLSI%29+at+Buy/27038827.html <p>H.C. Wainwright initiates coverage on TriSalus Life Sciences, Inc. (NASDAQ: TLSI) with a Buy rating and a price target of $11.00.</p><p>For an analyst ratings summary and ratings history on TriSalus Life Sciences, Inc. <a href="http://www.streetinsider.com/rating_history.php?q=TLSI">click here</a>. For more ratings news on TriSalus Life Sciences, Inc. <a href="http://www.streetinsider.com/stock_lookup_news.php?q=TLSI&amp;type=analyst">click here</a>.</p><p>Shares of TriSalus Life Sciences, Inc. closed at $4.73 yesterday.</p> http://www.streetinsider.com/New+Coverage/H.C.+Wainwright+Starts+TriSalus+Life+Sciences%2C+Inc.+%28TLSI%29+at+Buy/27038827.html Wed, 09 Sep 2026 06:12:24 -0400 TLSI http://www.streetinsider.com/Earnings/TriSalus+Life+Sciences+%28TLSI%29+Misses+Q2+EPS+by+1c/26886835.html <p>TriSalus Life Sciences (NASDAQ: TLSI) reported Q2 EPS of ($0.16), $0.01 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $11.41 million versus the consensus estimate of $10.79 million.</p><p>For earnings history and earnings-related data on TriSalus Life Sciences (TLSI) <a href="http://www.streetinsider.com/ec_earnings.php?q=TLSI">click here</a>.</p> http://www.streetinsider.com/Earnings/TriSalus+Life+Sciences+%28TLSI%29+Misses+Q2+EPS+by+1c/26886835.html Fri, 07 Aug 2026 06:09:01 -0400 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html <p class="bwalignc"> <i>Generated second quarter revenue of $11.4 million and expanded commercial organization to support future growth and broader market penetration</i> </p><p class="bwalignc"> <i>Maintains 2026 revenue guidance of $54 million to $57 million</i> </p><p class="bwalignc"> <i>Hosting Conference Call and Webcast today at 4:30pm ET</i> </p> <p> DENVER--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announced financial results for the quarter ended June 30, 2026, and provided an operational update. </p><p> “We delivered a second quarter marked by year-over-year and strong http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+Reports+Second+Quarter+2026+Results/26883457.html Thu, 06 Aug 2026 16:05:00 -0400 A.28005717 A.40221050 O.20020231 O.20042365 O.50377300 TLSI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TriSalus+Life+Sciences%2C+++For%3A+Jun+30/26883624.html si-local-file:///var/storage/secattach/20260806/26883624.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TriSalus+Life+Sciences%2C+++For%3A+Jun+30/26883624.html Thu, 06 Aug 2026 16:05:00 -0400 O.50377300 TLSI http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TriSalus+Life+Sciences%2C+++For%3A+Jun+30/26883624.html si-local-file:///var/storage/secattach/20260806/26883624.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++TriSalus+Life+Sciences%2C+++For%3A+Jun+30/26883624.html Thu, 06 Aug 2026 16:05:00 -0400 O.50377300 TLSI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TriSalus+Life+Sciences%2C+++For%3A+Aug+06/26883321.html si-local-file:///var/storage/secattach/20260806/26883321.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TriSalus+Life+Sciences%2C+++For%3A+Aug+06/26883321.html Thu, 06 Aug 2026 16:02:00 -0400 O.50377300 TLSI http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TriSalus+Life+Sciences%2C+++For%3A+Aug+06/26883321.html si-local-file:///var/storage/secattach/20260806/26883321.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++TriSalus+Life+Sciences%2C+++For%3A+Aug+06/26883321.html Thu, 06 Aug 2026 16:02:00 -0400 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26834824.html <p> WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings on Tuesday, August 11 and Wednesday, August 12, and participate in a fireside chat on Wednesday, August 12 at 8:30 a.m. ET. </p><p> A webcast replay of the corporate overview will be available for http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26834824.html Wed, 29 Jul 2026 16:05:00 -0400 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26834824.html <p> WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings on Tuesday, August 11 and Wednesday, August 12, and participate in a fireside chat on Wednesday, August 12 at 8:30 a.m. ET. </p><p> A webcast replay of the corporate overview will be available for http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26834824.html Wed, 29 Jul 2026 16:05:00 -0400 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26834824.html <p> WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings on Tuesday, August 11 and Wednesday, August 12, and participate in a fireside chat on Wednesday, August 12 at 8:30 a.m. ET. </p><p> A webcast replay of the corporate overview will be available for http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26834824.html Wed, 29 Jul 2026 16:05:00 -0400 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26834824.html <p> WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, today announced that Mary Szela, Chief Executive Officer and President, and David Patience, Chief Financial Officer, will participate in the Canaccord Genuity 46th Annual Growth Conference. Management will participate in one-on-one meetings on Tuesday, August 11 and Wednesday, August 12, and participate in a fireside chat on Wednesday, August 12 at 8:30 a.m. ET. </p><p> A webcast replay of the corporate overview will be available for http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26834824.html Wed, 29 Jul 2026 16:05:00 -0400 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call/26779628.html <p> WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the results will be issued prior to the call. </p><p> Parties interested in participating by phone should register using this <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI42f3cd7edd9e44be8ee085740704dc18&amp;esheet=54571724&amp;newsitemid=20260716428515&amp;lan=en-US&amp;anchor=online+form&amp;index=1&amp;md5=b69cf6f56fd9e6c5f4641d565424e1be" shape="rect">online form</a>. After registering for http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call/26779628.html Thu, 16 Jul 2026 16:05:00 -0400 O.50377300 TLSI http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call/26779628.html <p> WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the results will be issued prior to the call. </p><p> Parties interested in participating by phone should register using this <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI42f3cd7edd9e44be8ee085740704dc18&amp;esheet=54571724&amp;newsitemid=20260716428515&amp;lan=en-US&amp;anchor=online+form&amp;index=1&amp;md5=b69cf6f56fd9e6c5f4641d565424e1be" shape="rect">online form</a>. After registering for http://www.streetinsider.com/Press+Releases/TriSalus+Life+Sciences+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call/26779628.html Thu, 16 Jul 2026 16:05:00 -0400 O.50377300 TLSI http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call/26779628.html <p> WESTMINSTER, Colo.--(BUSINESS WIRE)-- TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immunotherapeutic to transform outcomes for patients with solid tumors, today announced that it will host a conference call and webcast on Thursday, August 6, 2026 at 4:30 PM eastern time to discuss its financial results for the quarter ended June 30, 2026. A press release detailing the results will be issued prior to the call. </p><p> Parties interested in participating by phone should register using this <a target="_blank" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fregister-conf.media-server.com%2Fregister%2FBI42f3cd7edd9e44be8ee085740704dc18&amp;esheet=54571724&amp;newsitemid=20260716428515&amp;lan=en-US&amp;anchor=online+form&amp;index=1&amp;md5=b69cf6f56fd9e6c5f4641d565424e1be" shape="rect">online form</a>. After registering for http://www.streetinsider.com/Business+Wire/TriSalus+Life+Sciences+to+Host+Second+Quarter+2026+Financial+Results+Conference+Call/26779628.html Thu, 16 Jul 2026 16:05:00 -0400 O.50377300 TLSI